# A Study to Compare the Conversion to Prograf® (Tacrolimus) to the Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure

> **NCT00510913** · PHASE4 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 450 (estimated)

## Conditions studied

- Graft Rejection
- Kidney Transplantation

## Interventions

- **DRUG:** tacrolimus

## Key facts

- **NCT ID:** NCT00510913
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-02
- **Primary completion:** —
- **Final completion:** 2000-09
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2007-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00510913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00510913, "A Study to Compare the Conversion to Prograf® (Tacrolimus) to the Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00510913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*